TLDR Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.
Elevated levels of IL-17A are linked to the severity of alopecia areata (AA) and vary among different clinical subtypes, indicating its involvement in disease progression and phenotype differences. IL-23 is consistently elevated in AA, suggesting its potential as a biomarker for monitoring disease activity. These results enhance the understanding of cytokine dysregulation in AA and could guide the development of future treatments.
April 2023 in “The Egyptian Journal of Hospital Medicine” Higher Interleukin 17A levels may indicate more severe alopecia areata.
October 2021 in “Dermatology Reports” Higher IL-17A levels indicate more severe alopecia areata.
391 citations
,
January 2010 in “Journal of The American Academy of Dermatology” Half of people with Alopecia Areata may see hair regrowth within a year without treatment, but recovery is unpredictable.
37 citations
,
December 2021 in “Cells” Alopecia areata severity and treatment response are linked to specific cytokine levels.
1 citations
,
August 2023 in “Biomolecules” Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.
57 citations
,
April 2019 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata involves immune system imbalances that may lead to depression and anxiety.
1 citations
,
January 2025 in “Frontiers in Immunology” Genetically at-risk healthy people show similar immune issues as those with Pemphigus vulgaris or Alopecia areata.
May 2024 in “Frontiers in Immunology” Type-2 immunity may influence skin diseases and could be targeted for treatment.
5 citations
,
May 2023 in “Frontiers in immunology” Environmental factors like diet and vitamin levels, especially Vitamin D, can affect autoimmune diseases differently, with lifestyle changes potentially improving outcomes.